Pronidesivir (GS-441524) Instructions for Use
Feline Infectious Peritonitis (FIP) is a severe and often fatal disease caused by the feline coronavirus. Symptoms include loss of appetite, lethargy, fever, abdominal and thoracic fluid accumulation, lymph node enlargement, inflammatory granulomas, neurological damage, and uveitis. Effective treatment options are limited, but NeoFipronis (Pronidesivir), featuring the active ingredient GS-441524, has emerged as a groundbreaking antiviral therapy for FIP.
NeoFipronis (Pronidesivir) is the world's first officially registered oral medication targeting FIP, approved by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026. It is a safe, non-invasive treatment with rapid absorption, quick onset of action, good tolerance, and minimal side effects. Its proven efficacy during extensive research and clinical trials makes it a vital tool in the fight against feline coronavirus-induced FIP.
The active compound, GS-441524, is a nucleoside analog that inhibits viral replication effectively. Its mechanism involves interfering with the viral RNA synthesis, shutting down the virus's ability to reproduce within infected cells. NeoFipronis’s targeted approach results in significant clinical improvement, often reversing or stabilizing symptoms associated with FIP.
Usage Instructions
NeoFipronis should be administered based on the cat's body weight. The standard dosage is 15 mg per kilogram, approximately half a tablet per day. For neurological or ocular forms of FIP, veterinary guidance may recommend increasing the dose to 30 mg/kg. The medication is recommended to be given once daily, preferably on an empty stomach—either one hour before feeding or two hours after.
Duration and Monitoring
A full course of treatment should be maintained for no less than 12 weeks. Consistency is critical; missed doses can compromise treatment efficacy. During therapy, closely monitor the cat’s appetite, body temperature, behavioral changes, and overall wellbeing. Regular blood tests should be conducted to assess liver and kidney functions, ensuring no adverse effects develop during prolonged treatment.
Precautions & Recommendations
Although NeoFipronis is classified as an over-the-counter product in some regions, veterinary supervision is strongly advised to optimize therapy and monitor for potential side effects. Precautions should include avoiding abrupt discontinuation of treatment, which may lead to viral rebound.
Safety and Purchase
NeoFipronis is strictly for veterinary use in cats; it is unsafe for human consumption. To guarantee authentic and quality-assured products, purchase only through official NeoFipronis authorized websites or recognized veterinary pharmacies. Maintaining high standards ensures the integrity of the medication and maximizes the chances of successful FIP management.
Final Notes
NeoFipronis (Pronidesivir, GS-441524) represents a significant advance in feline medicine, offering hope for cats suffering from FIP. Its ease of oral administration, rapid action, and proven effectiveness make it a preferred choice among veterinarians and pet owners alike. Strict adherence to dosage, duration, and veterinary guidance is essential for achieving the best therapeutic outcomes. With continued research and clinical success, NeoFipronis is set to become a cornerstone in FIP treatment and improved feline health worldwide.
